TRACON Pharmaceuticals $TCON entered in a strategic licensing collaboration with Janssen Pharmaceutica N.V. $JNJ for two of its unique oncology assets. The licensing agreement also includes a $5M equity investment in TRACON by Johnson & Johnson Innovation through the purchase of common stock at $5.95 per share.